MDGL vs RDY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
MDGL presents a stark contrast between fundamental financial health and explosive growth potential. The Piotroski F-Score of 1/9 indicates severe underlying financial weakness and a lack of operational efficiency, while the absence of an Altman Z-Score prevents a definitive bankruptcy risk assessment. However, this is offset by massive YoY revenue growth of 210.80% and a strong liquidity position (Current Ratio 4.01). The stock trades at a significant premium with a Price/Book of 19.65, and bearish insider activity from the CEO and CFO suggests a disconnect between analyst optimism and internal sentiment.
RDY exhibits a stable financial foundation with a Piotroski F-Score of 4/9 and very low leverage, but it is severely overvalued based on deterministic models. The current price of $13.72 trades at a massive premium to both the Graham Number ($3.61) and the Intrinsic Value ($5.04). This valuation gap is exacerbated by negative earnings growth (-14.30%) and a high PEG ratio of 3.77, suggesting the market is pricing in growth that is not currently manifesting in the data. While the balance sheet is healthy, the combination of bearish technicals and fundamental overvaluation makes the risk-reward profile unattractive.
Compare Another Pair
Related Comparisons
MDGL vs RDY: Head-to-Head Comparison
This page compares Madrigal Pharmaceuticals, Inc. (MDGL) and Dr. Reddy's Laboratories Limited (RDY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.